Sunday, June 4, 2023
SCIENMAG: Latest Science and Health News
No Result
View All Result
  • Login
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
No Result
View All Result
Scienmag - Latest science news from science magazine
No Result
View All Result
Home SCIENCE NEWS Social & Behavioral Science

IVI and the Ministry of Health and Welfare of the Republic of Korea urge global action on enhancing vaccine manufacturing during the 76th World Health Assembly

May 24, 2023
in Social & Behavioral Science
0
Share on FacebookShare on Twitter

The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, and the Ministry of Health and Welfare (MOHW) of the Republic of Korea gathered ministers of health and global health and immunization leaders for Empowering local biomanufacturing: How to equip countries for current and future infectious disease outbreaks, a side event of the 76th World Health Assembly.

IVI-MOHW ROK Side Event at WHA76

Credit: IVI

The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, and the Ministry of Health and Welfare (MOHW) of the Republic of Korea gathered ministers of health and global health and immunization leaders for Empowering local biomanufacturing: How to equip countries for current and future infectious disease outbreaks, a side event of the 76th World Health Assembly.

 

Sponsored by Brazil, Ghana, Kenya, Rwanda, Sweden, and Thailand, this event brought together officials from governments and the public and private sectors to discuss needs and opportunities for a coordinated and highly skilled global biomanufacturing workforce and infrastructure.

 

Dr. Jerome Kim, Director General of IVI, said: “Increasing the global capacity to manufacture vaccines and other health products is a critical factor in ensuring countries are able to respond to outbreaks of endemic and emerging infectious diseases with equity and efficiency. In IVI’s first year with observer status at the World Health Assembly, we are proud to organize this side event with the Republic of Korea, an urgent and complementary conversation to our ongoing efforts to train a biomanufacturing workforce through the Global Training Hub for Biomanufacturing.”

 

Dr. Youngmee Jee, Commissioner of the Korea Disease Control and Prevention Agency, said: “Korea was designated as a global bio human resource training institution last year and is already conducting the educational program…I hope countries around the world are able to advance their ability to access vaccines equally.”

 

The Honorable Kwaku Agyeman-Manu, Minister for Health of Ghana; Sir Jeremy Farrar, Chief Scientist of the WHO; and Olivia Wigzell, Director-General of Sweden’s National Board of Health and Welfare, gave high-level remarks to open the discussions.

 

The event continued with three sessions:

  • Sharing the best practices of WHO member states and their strategies, where country representatives spoke on learnings from the COVID-19 pandemic and efforts to build up local vaccine manufacturing capacity.
    • HWANG Seung Hyun, Director General, Global Vaccine Hub, Ministry of Health and Welfare, Republic of Korea
    • Tiago Rocca, Director of Strategic Partnerships and New Businesses, Instituto Bhutantan, Brazil
    • Rabera Kenyanya, Kenya BioVax Institute, Kenya
    • Dr. Yvan Butera, Minister of State, Ministry of Health, Rwanda
    • Nakorn Premsri, Director, National Vaccine Institute, Thailand

 

  • Global biomanufacturing capacity-building programs, where IVI and Korean industry partners discussed the operations and takeaways of the Global Training Hub for Biomanufacturing program.
    • Manki Song, Deputy Director General of Science, IVI
    • LEE Jin Woo, K-NIBRT
    • CHA Sang Hoon, Chairman, K-BIO Health

 

  • Gaps and challenges for global biomanufacturing capacity-building and fostering opportunities with better international cooperation mechanisms, a panel discussion moderated by IVI and featuring leaders from CEPI and the WHO.
    • Jerome Kim, Director General, IVI
    • William Ampofo, Chairman, African Vaccine Manufacturing Initiative
    • Frederik Kristensen, Deputy CEO, Coalition for Epidemic Preparedness Innovations
    • Rogério Gaspar, Director, Regulation and Prequalification, WHO

 

Empowering local biomanufacturing: How to equip countries for current and future infectious disease outbreaks took place on Tuesday, May 23, 2023, at the Hotel President Wilson in Geneva.

 

###

 

About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.

IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that is currently under assessment for WHO PQ.

IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, and Finland provide state funding. For more information, please visit https://www.ivi.int.

 

 

About the Global Training Hub for Biomanufacturing (GTH-B)

The COVID-19 pandemic tragically demonstrated that the international community is only safe when everyone is safe. Vaccines were a primary line of defense against COVID-19, helping some, but not all, countries overcome and build back from the pandemic. A grave imbalance of vaccine access and equity halted global recovery.

To secure vaccines and better prepare for current and future outbreaks, low- and middle-income countries around the world have seriously taken into consideration the need to build local vaccine manufacturing capacity. To meet this need, a critical resource gap is the availability of skilled, trained personnel in this highly technologically demanding field. To support these countries, the Korean Ministry of Health and Welfare (MOHW) established “Global Bio Manufacturing Workforce Training” with support from the WHO, including WHO Academy.

IVI administers training courses through this global program, the first of its kind supported by the Government of Korea, to provide essential, practical knowledge designed to strengthen professional capacity in all aspects of biomanufacturing.



Tags: 76thactionassemblyEnhancingglobalhealthIVIKoreamanufacturingMinistryRepublicurgevaccinewelfareWorld
Share25Tweet16Share4ShareSendShare
  • Nearly 70% of private label avocado oil rancid or mixed with other oils

    65 shares
    Share 26 Tweet 16
  • Null results research now published by major behavioral medicine journal

    782 shares
    Share 313 Tweet 196
  • UC Davis C-STEM trains Redlands teachers on bringing computer science into math

    65 shares
    Share 26 Tweet 16
  • Mozart may reduce seizure frequency in people with epilepsy

    67 shares
    Share 27 Tweet 17
  • The promise of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

    64 shares
    Share 26 Tweet 16
  • Phase 3 SWOG Cancer Research Network trial, led by a City of Hope researcher, demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy

    64 shares
    Share 26 Tweet 16
ADVERTISEMENT

About us

We bring you the latest science news from best research centers and universities around the world. Check our website.

Latest NEWS

Null results research now published by major behavioral medicine journal

Why expensive wine appears to taste better

Element creation in the lab deepens understanding of surface explosions on neutron stars

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 206 other subscribers

© 2023 Scienmag- Science Magazine: Latest Science News.

No Result
View All Result
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US

© 2023 Scienmag- Science Magazine: Latest Science News.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In